Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
复制标题
DOI：
10.1007/s13300-017-0324-x
复制
发表时间：
2017-12
期刊：
影响因子：
--
通讯作者：
Bozek T
中科院分区：
文献类型：
--
作者：
Berkovic MC;Bilic-Curcic I;Herman Mahecic D;Gradiser M;Grgurevic M;Bozek T
胰高血糖素样肽 1 (GLP-1) 受体激动剂 (RA) 被推荐用于治疗 2 型糖尿病 (T2DM)，而利拉鲁肽是全球使用最广泛的药物。我们在常规临床实践中对调节不佳的 T2DM 患者进行 36 个月的随访，评估了利拉鲁肽的血糖疗效和血糖外效应，并试图确定治疗反应者的表型。总共包括 207 人。主要终点是 HbA1c < 7.0% 和/或体重减轻的参与者比例。次要终点包括 3 年随访期间血脂、血压、空腹 C 肽和抗糖尿病治疗的变化。 89.8% 的参与者已服用至少两种抗糖尿病药物，18% 的参与者服用胰岛素。受试者的平均年龄为 53.28 ± 9.42 岁，糖尿病病程为 8.29 ± 4.89 年。基线 HbA1c 为 8.5 ± 1.3%，体重指数 (BMI) 为 39 ± 4.5 kg/m2。 84.4% 的参与者观察到 HbA1c 降低，89.2% 的参与者平均体重减轻 5 公斤。 76.2% 的患者取得了复合结果（HbA1c 降低且体重减轻）。接受利拉鲁肽治疗 6 个月后，38.1% 的参与者达到了 < 7% 的目标 HbA1c 水平。 50.8% 的受试者的这种效果维持了 36 个月。 24 个月后，C 肽明显增加 (p = 0.030)。参与者的收缩压 (BP) 显着降低 (p = 0.003)，而舒张压、血脂或肝酶没有影响。使用磺酰脲类药物治疗的参与者人数从 60.8% 减少至 17.5%，而使用胰岛素和钠-葡萄糖协同转运蛋白 2 (SGLT-2) 抑制剂治疗的参与者人数则增加（分别为 17.6% 至 24.6% 和 2.5% 至 36.8%）。 HbA1c 降低持久性的独立预测因素是初始 BMI (p = 0.004)、HbA1c (p < 0.001)、收缩压 (p = 0.007) 和胆固醇 (p = 0.020)。此外，女性性别和糖尿病病程较短是 HbA1c 降低的独立预测因素。当用于治疗患有 T2DM 的肥胖调节不良个体时，利拉鲁肽显示出持续的血糖和血糖外效应。
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are recommended therapy for type 2 diabetes (T2DM) and liraglutide is the most used worldwide. We assessed the glycemic efficacy and extra-glycemic effects of liraglutide during 36 months’ follow-up of individuals with poorly regulated T2DM under routine clinical practice and sought to identify the phenotype of treatment responders. A total of 207 individuals were included. The primary endpoint was the proportion of participants with HbA1c < 7.0% and/or weight reduction. Secondary endpoints included changes in lipids, blood pressure, fasting c-peptide, and antidiabetic treatment during follow-up of 3 years. Liraglutide was prescribed to 89.8% of participants already on at least two antidiabetic medications and 18% on insulin. Subject's mean age was 53.28 ± 9.42 years with duration of diabetes 8.29 ± 4.89 years. Baseline HbA1c was 8.5 ± 1.3% and body mass index (BMI) was 39 ± 4.5 kg/m2. Reduction of HbA1c was observed in 84.4% of participants, and 89.2% experienced average weight reduction of 5 kg. A composite outcome (reduction of HbA1c with any weight loss) was achieved in 76.2% of patients. After 6 months on liraglutide treatment, 38.1% of participants achieved target HbA1c level < 7%. This effect was maintained for 36 months in 50.8% of subjects. Increase in c-peptide was evident after 24 months (p = 0.030). Participants experienced a significant reduction in systolic blood pressure (BP) (p = 0.003), while there was no effect on diastolic BP, lipid profile, or liver enzymes. The number of participants treated with sulfonylurea decreased from 60.8% to 17.5%, while the number treated with insulin and sodium-glucose co-transporter-2 (SGLT-2) inhibitor increased (17.6% to 24.6% and 2.5% to 36.8%, respectively). Independent predictors of durability of HbA1c reduction were initial BMI (p = 0.004), HbA1c (p < 0.001), systolic BP (p = 0.007), and cholesterol (p = 0.020). Moreover, female gender and shorter duration of diabetes were independent predictors for HbA1c reduction. Liraglutide shows sustained glycemic and extra-glycemic effects when used for treatment of obese poorly regulated individuals with T2DM.
登录
查看更多内容
影响因子：
16.2
作者：
Pennartz C;Schenker N;Menge BA;Schmidt WE;Nauck MA;Meier JJ
通讯作者：
Meier JJ
Liraglutide在现实世界中2型糖尿病治疗中的临床有效性：系统文献综述。
DOI：
10.1007/s13300-016-0180-0
发表时间：
2016-09
期刊：
Diabetes therapy : research, treatment and education of diabetes and related disorders
影响因子：
--
作者：
Ostawal A;Mocevic E;Kragh N;Xu W
通讯作者：
Xu W
影响因子：
3.8
作者：
Chitnis, Abhishek S.;Ganz, Michael L.;Hammer, Mette
通讯作者：
Hammer, Mette
影响因子：
16.2
作者：
通讯作者：
--
影响因子：
4.3
作者：
Khan, Muhammad;Ouyang, Jing;Joseph, Franklin
通讯作者：
Joseph, Franklin